Share Twitter LinkedIn Facebook Email C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses MRD Detection In MM at Lymphoma & Myeloma on October 18, 2018.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read